The health-related quality of life of sarcoma patients and survivors in germany—cross-sectional results of a nationwide observational study (Prosa)
Research output: Contribution to journal › Research article › Contributed › peer-review
Contributors
- National Center for Tumor Diseases Dresden
- University Cancer Centre Dresden
- Department of Internal Medicine I
- Department of Visceral, Thoracic and Vascular Surgery
- University Center for Orthopedics, Trauma and Plastic Surgery
- Center for Evidence-Based Healthcare
- TUD Dresden University of Technology
- Heidelberg University
- University of Münster
- Helios Hospital Group
- University of Greifswald
- University of Göttingen
- Johannes Gutenberg University Mainz
- Friedrich-Alexander University Erlangen-Nürnberg
- Heinrich Heine University Düsseldorf
- German Sarcoma Foundation
- The Scientific Institute of Office-based Hematologists and Oncologists
- Ulm University
- Inter-Local Joint Practice
- University Hospital Frankfurt
- Helios Hospital Emil von Behring
Abstract
Sarcomas are rare cancers with high heterogeneity in terms of type, location, and treatment. The health-related quality of life (HRQoL) of sarcoma patients has rarely been investigated and is the subject of this analysis. Adult sarcoma patients and survivors were assessed between September 2017 and February 2019 in 39 study centers in Germany using standardized, validated questionnaires (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)). Associated factors were analyzed exploratively using multivariable linear regressions. Among 1113 patients, clinically important limitations and symptoms were most pronounced in emotional (63%, 95% CI 60–66%), physical (60%, 95% CI 57–62%), role functioning (51%, 95% CI 48–54%), and pain (56%, 95% CI 53–59%) and fatigue (51%, 95% CI 48–54%). HRQoL differed between tumor locations with lower extremities performing the worst and sarcoma types with bone sarcoma types being most affected. Additionally, female gender, higher age, lower socioeconomic status, recurrent disease, not being in retirement, comorbidities, and being in treatment were associated with lower HRQoL. Sarcoma patients are severely restricted in their HRQoL, especially in functioning scales. The heterogeneity of sarcomas with regard to type and location is reflected in HRQoL outcomes. During treatment and follow-up, close attention has to be paid to the reintegration of the patients into daily life as well as to their physical abilities and emotional distress.
Details
Original language | English |
---|---|
Article number | 3590 |
Pages (from-to) | 1-19 |
Number of pages | 19 |
Journal | Cancers |
Volume | 12 |
Issue number | 12 |
Publication status | Published - Dec 2020 |
Peer-reviewed | Yes |
External IDs
ORCID | /0000-0001-9654-2207/work/142254152 |
---|
Keywords
Sustainable Development Goals
ASJC Scopus subject areas
Keywords
- Clinically important restrictions and symptoms, Health-related quality of life, Observational study, Rare disease, Sarcoma